Cytosorbents Appoints New VP of Marketing

Cytosorbents ( (CTSO) ) has shared an update.

On April 14, 2025, CytoSorbents Corporation announced the appointment of Thomas Shannon as Vice President of Marketing for North America. Shannon, with over 25 years of experience in commercializing cardiovascular and critical care technologies, will lead the marketing strategy for DrugSorb™-ATR in the U.S. and Canada. This appointment comes as the company prepares for the potential launch of DrugSorb-ATR, a device aimed at reducing perioperative bleeding in patients undergoing coronary artery bypass graft surgery while on blood thinners. The device is currently under review by the U.S. FDA and Health Canada, with regulatory decisions expected in 2025.

Spark’s Take on CTSO Stock

According to Spark, TipRanks’ AI Analyst, CTSO is a Neutral.

Cytosorbents’ stock faces significant financial challenges, including declining revenues, high leverage, and negative cash flows, necessitating strategic improvements. While recent earnings and corporate events show positive trends in revenue growth and liquidity, these are offset by technical and valuation concerns, leading to a cautious overall score.

To see Spark’s full report on CTSO stock, click here.

More about Cytosorbents

CytoSorbents Corporation is a leader in the treatment of life-threatening conditions in the intensive care unit and cardiac surgery through blood purification technologies. Their products, based on biocompatible polymer beads, are used to remove toxic substances from blood, addressing issues such as severe bleeding during cardiothoracic surgery and inflammation in critical illnesses. CytoSorbents’ technologies are applied in various medical devices, and their lead product, CytoSorb®, is approved in the European Union and distributed in over 70 countries.

YTD Price Performance: 5.65%

Average Trading Volume: 105,319

Technical Sentiment Signal: Strong Buy

Current Market Cap: $60.75M

See more data about CTSO stock on TipRanks’ Stock Analysis page.